Lithium Citrate
FDA-approved product (syrup, oral), marketed as Lithium Citrate, Lithonate, Potassium Citrate and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia (phenotype)
- Bipolar I disorder
- Major depressive disorder
- Renal tubular acidosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Potassium; Salt solutions
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Lithium Citrate, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA11.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae10.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lithium Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- RisdiplamExisting use: Atrophy, Proximal spinal muscular atrophy, Spinal muscular atrophy54.8% AI-predicted activityagainst MRSA33 registered studies
- Amphotericin BExisting use: Aspergillosis, Candidiasis, Cryptococcal meningitis and 7 more54.7% AI-predicted activityagainst MRSA50+ registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension54.7% AI-predicted activityagainst MRSA50+ registered studies
- AlprazolamExisting use: Anxiety, Anxiety disorder, Generalized anxiety disorder and 1 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more54.6% AI-predicted activityagainst MRSA50+ registered studies
- RevefenacinExisting use: Airway obstruction, Chronic obstructive pulmonary disease54.6% AI-predicted activityagainst MRSA20 registered studies
- CobicistatExisting use: HIV infection, HIV-1 infection, Infection54.6% AI-predicted activityagainst MRSA50+ registered studies
- ErdafitinibExisting use: Bladder tumor, Cancer, Neoplasm and 2 more54.6% AI-predicted activityagainst MRSA43 registered studies
- AvanafilExisting use: Erectile dysfunction, Impotence54.5% AI-predicted activityagainst MRSA24 registered studies
- Conivaptan HydrochlorideExisting use: Cardiovascular disease, Heart failure54.5% AI-predicted activityagainst MRSA21 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more54.4% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
NCT00251316 · start 2005-11
Registered record
- Registry ID
- NCT00251316
- Conditions
- Thyroid Cancer; Differentiated Thyroid Carcinoma
- Interventions
- Lithium Carbonate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2011-12
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThyroid Cancer; Differentiated Thyroid CarcinomaInterventionLithium Carbonate; PlaceboPhasePhase 2Registry statusCompletedTreatment of Mania Symptoms With Drug Therapy
NCT00183443 · start 2005-02
Registered record
- Registry ID
- NCT00183443
- Conditions
- Bipolar Disorder; Schizophrenia
- Interventions
- Divalproex-extended release (DVP-ER); Lithium; Quetiapine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-02
- Completion
- 2010-11
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar Disorder; SchizophreniaInterventionDivalproex-extended release (DVP-ER); Lithium; QuetiapinePhasePhase 3Registry statusCompletedOlanzapine Versus Comparator in the Treatment of Bipolar Disorder
NCT00485680 · start 2003-12
Registered record
- Registry ID
- NCT00485680
- Conditions
- Bipolar Disorder
- Interventions
- Olanzapine Hydrochloride; Lithium Carbonate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-12
- Completion
- 2005-06
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar DisorderInterventionOlanzapine Hydrochloride; Lithium CarbonatePhasePhase 3Registry statusCompletedAtypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
NCT01977300 · start 2003-01
Registered record
- Registry ID
- NCT01977300
- Conditions
- Bipolar I Disorder
- Interventions
- Valproate; Lithium; Risperidone; Olanzapine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2011-08
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar I DisorderInterventionValproate; Lithium; Risperidone; Olanzapine +1 morePhasePhase 3Registry statusCompletedBioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions
NCT00601575 · start 2002-10
Registered record
- Registry ID
- NCT00601575
- Conditions
- Bipolar Disorder
- Interventions
- Lithium
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-10
- Completion
- 2002-11
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar DisorderInterventionLithiumPhaseNot applicableRegistry statusCompleted